| Vol. 13.30 – 19 August, 2021 |
| |
|
|
| Investigators evaluated commercial umbilical cord allograft products for viable cells, colony forming unit–fibroblasts, and protein makeup. [American Journal of Sports Medicine] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| A microsphere embedded osteoinductive decellularized bone ECM/oleoyl chitosan based hydrogel construct was developed as a matrix allowing dual delivery of an anti-resorptive drug and BMP-2 for a focal tibial defect in a rabbit model. Amniotic membrane-derived stem cells cultivated on the hydrogel construct demonstrated excellent biocompatibility, cell viability, and active proliferation potential. [Journal of Materials Chemistry B] |
|
|
|
| Researchers compared the therapeutic potential of induced pluripotent stem cells differentiation into MSCs generated from urinary epithelial cells with the available umbilical cord MSCs. [Journal of Cellular and Molecular Medicine] |
|
|
|
| Investigators explored the repair effect of human umbilical cord MSCs-derived extracellular vesicles on spinal cord injury. [Cell Death Discovery] |
|
|
|
| Scientists explored the role of concentrated growth factor membranes in periodontal tissue regeneration mediated by human umbilical cord MSCs. [Stem Cells International] |
|
|
|
| The authors revealed that the NRF2-conditioned medium protected the wharton’s jelly derived-MSCs against H2O2-induced toxicity in vitro. [Journal of Tissue Viability] |
|
|
|
|
| Most of the 416 published trials evaluated MSCs’ effectiveness in treating cardiovascular diseases, GvHD, and brain and neurological disorders, although some trials sought to treat immune system diseases and wounds and to restore tissue. [Stem Cell Reviews and Reports] |
|
|
|
| Scientists explore the potential of transplanting exogenous umbilical cord blood cells and mobilizing host resident stem cells in vascular dementia and aging. [Stem Cell Reviews and Reports] |
|
|
|
|
| ERS Genomics Limited announced a non-exclusive license agreement granting CET access to ERS Genomics’ CRISPR/Cas9 patent portfolio. [ERS Genomics Limited] |
|
|
|
|
| October 17 – 19, 2021 Virtual |
|
|
|
|
|
| Baylor College of Medicine – Houston, Texas, United States |
|
|
|
| Danaher – Toronto, Ontario, Canada |
|
|
|
| Michigan State University – East Lansing, Michigan, United States |
|
|
|
| UCLA Jules Stein Eye Institute – Los Angeles, California, United States |
|
|
|
| Princess Margaret Cancer Centre – Toronto, Ontario, United States |
|
|
|
|